# US 2019/0167573 A1 · Drug delivery systems and applications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167573 A1
- Document ID: US20190167573A1
- Status: Published application
- Kind: A1
- Application number: 16/203,782
- Filed: 2018-11-29
- Published: 2019-06-06
- Earliest claimed: 2011-09-16
- Assignees: Incept, LLC
- Applicants: Incept, LLC
- Inventors: Peter Jarrett; Rami El-Hayek; Amarpreet S. Sawhney; Sarah Guedez
- Web page: https://patentgrep.com/patent/US20190167573A1

## CPC

- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/5015: {Organic compounds, e.g. fats, sugars}
- A61P 27/02: Ophthalmic agents
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Certain embodiments of the invention include medical materials and methods comprising a biodegradable hydrophilic hydrogel comprising dispersed lipophilic particles that comprise a therapeutic agent, wherein the lipophilic particles have a low water solubility in physiological saline at physiological temperature.

## Claims

### Claim 1

A medical material comprising
a biodegradable hydrophilic hydrogel comprising dispersed lipophilic particles that comprise a low water soluble lipophilic compound and further comprise a therapeutic agent that comprises a protein having a secondary and/or a tertiary structure, wherein the lipophilic particles are solid at 20° C. and have a low water solubility in physiological saline at physiological temperature, with the protein being released from the microparticles and the medical material in a conformation that is substantially free of denaturation as measurable by enzyme-linked immunosorbent assay and isoelectric focusing.

### Claim 2 (depends on 1)

The medical material of claim 1 wherein the low water soluble lipophilic compound has a molecular mass of no more than about 2000 Daltons.

### Claim 3 (depends on 1)

The medical material of claim 1 wherein the particles have a melting point of between about 25° C. and about 60° C.

### Claim 4 (depends on 3)

The medical material of claim 3 wherein the therapeutic agent comprises a drug with a log P of at least about 2.

### Claim 5 (depends on 4)

The medical material of claim 4 wherein the low water soluble lipophilic compound has a log P of at least about 2.

### Claim 6 (depends on 3)

The medical material of claim 3 wherein the lipophilic particles are a solid at physiological temperature.

### Claim 7 (depends on 1)

The medical material of claim 1 wherein the hydrogel comprises covalently crosslinked hydrophilic polymers.

### Claim 8 (depends on 7)

The medical material of claim 7 wherein the polymers comprise a member chosen from the group consisting of polyethylene oxide, polyvinyl pyrrolidinone, hyaluronic acid, and polyhydroxyethlymethacrylate.

### Claim 9 (depends on 1)

The medical material of claim 1 wherein the hydrogel biodegrades by spontaneous hydrolysis of hydrolytically degradable linkages chosen from the group consisting of esters, carbonates, anhydrides and orthocarbonates.

### Claim 10 (depends on 1)

The medical material of claim 1 wherein the hydrogel comprises ionically crosslinked polymers.

### Claim 11 (depends on 10)

The medical material of claim 10 wherein the polymers comprise a member chosen from the group consisting of alginate, gellan, collagen, and polysaccharide.

### Claim 12 (depends on 1)

The medical material of claim 1 wherein a cumulative amount of release of the agent reaches 90% of the agent at a time between about 1 month and about 6 months after placement of the hydrogel and particles in a saline solution.

### Claim 13 (depends on 1)

The medical material of claim 1 wherein a cumulative amount of release of the agent reaches 90% of the agent at a time between about 5 days and about 1 month after placement of the hydrogel and particles in a saline solution.

### Claim 14 (depends on 1)

The medical material of claim 1 wherein the lipophilic particles comprise at least one member chosen from the group consisting of lauric acid, capric acid, methyl stearate, and methyl palmitate.

### Claim 15

A process of making a medical material comprising
coating a protein powder with a low water soluble lipophilic compound to make particles,
dispersing the particles in a medical hydrogel implant,
with the protein having a secondary and/or a tertiary structure and being released from the microparticles and the medical material in a conformation that is substantially free of denaturation as measurable by enzyme-linked immunosorbent assay and isoelectric focusing.

### Claim 16 (depends on 15)

The process of claim 15 wherein the lipophilic compound comprises a fatty acid with a melting point between about 25° C. and about 60° C.

### Claim 17 (depends on 15)

The process of claim 15 wherein the low water soluble lipophilic compound has a molecular mass of no more than about 2000 Daltons.

### Claim 18 (depends on 15)

The process of claim 15 wherein the lipophilic compound is provided as a melt, and wherein coating a protein powder with a lipophilic compound to make particles comprises mixing the powder with the melt to coat the powder with the compound, cooling the mixture to a solid, and breaking up the solid to form the particles.

### Claim 19 (depends on 15)

The process of claim 15 wherein the hydrogel is formed in a shape chosen from the group consisting of a rod and a disc.

### Claim 20 (depends on 15)

The process of claim 15 further comprising dehydrating the hydrogel for storage.

### Claim 21 (depends on 15)

The process of claim 15 wherein the hydrogel is formed in situ in a patient.

### Claim 22 (depends on 21)

The process of claim 21 wherein the particles are mixed with a precursor that is reacted to form the hydrogel in situ.

### Claim 23 (depends on 22)

The process of claim 22 wherein the precursor is reacted by a technique chosen from the group consisting of free radical polymerization and thermally sensitive gelation in response to a body temperature of the patient.

### Claim 24 (depends on 22)

The process of claim 22 wherein the precursor is a first precursor comprising nucleophilic groups, and further comprising reacting the first precursor with the second precursor comprising electrophilic groups, with the electrophilic groups and nucleophilic groups reacting with each other to form covalent bonds to thereby form the hydrogel.

### Claim 25 (depends on 15)

The process of claim 15 wherein coating a protein powder with a lipophilic compound to make particles comprises
mixing the protein powder with a lipophilic compound to form a mixture of the powder and the compound,
dispersing the mixture into a solution to form droplets of the mixture, and
cooling the droplets to a solid phase and thereby form the particles.

### Claim 26 (depends on 25)

The process of claim 25 wherein cooling the droplets comprises providing the solution as a non-solvent for the lipophilic compound at a temperature below the melting point of the lipophilic compound.

### Claim 27 (depends on 15)

The process of claim 15 wherein coating a peptide powder with a lipophilic compound to make particles comprises
mixing the powder and a solution of the lipophilic compound to make a suspension that comprises droplets of the powder and the lipophilic compound,
and cooling the droplets to thereby form the particles.

### Claim 28 (depends on 15)

The process of claim 15 further comprising providing the hydrogel as a plurality of hydrogel particles.

### Claim 29 (depends on 15)

The process of claim 15 wherein the particles are dehydrated for storage and, at the time of use, mixed with a carrier to form a slurry that is injectable into a patient.

### Claim 30 (depends on 15)

The process of claim 15 wherein the particles have a melting point between about 25° C. and about 60° C.

### Claim 31 (depends on 15)

The process of claim 15 wherein the particles are solid at physiological temperatures in vivo and have a melting point of less than about 60° C.

### Claim 32 (depends on 15)

The process of claim 15 wherein the particles are made, and the hydrogel is created, without exposure of the peptide to a solvent.

### Claim 33 (depends on 15)

The process of claim 15 wherein the peptide in the particle is substantially free of denaturation as measurable by comparison of the protein in the particle to the protein before mixing with the hydrophobic coating, with the comparison being made by enzyme-linked immunosorbent assay and isoelectric focusing.

### Claim 34 (depends on 15)

The process of claim 15 wherein, after placement in an excess of physiological solution at physiological temperature, a cumulative amount of release of the agent reaches 90% of the agent at a time between about 1 and about 6 months after placement of the hydrogel and particles in a saline solution.

### Claim 35 (depends on 15)

The process of claim 15 wherein, after placement in an excess of physiological solution at physiological temperature, a cumulative amount of release of the agent reaches 90% of the agent at a time between about 5 days and about 1 month after placement of the hydrogel and particles in a saline solution.

### Claim 36

A method of delivering a therapeutic agent to a patient comprising placing a hydrogel in a patient that comprises a collection of particles that comprise a low water soluble lipophilic compound and a therapeutic agent, with the agent being released into the patient.

### Claim 37 (depends on 36)

The method of claim 36 wherein the hydrogel is molded into a unitary implant that is subsequently implanted in the patient.

### Claim 38 (depends on 36)

The method of claim 36 wherein the implant is implanted in a substantially dehydrated state.

### Claim 39 (depends on 36)

The method of claim 36 wherein the hydrogel is an injectable suspension or slurry that is injected into the patient.

### Claim 40 (depends on 36)

The method of claim 36 wherein the hydrogel is placed into the patient at or near an eye at a location chosen from the group consisting of intravitreal, cornea, retinal, subconjunctival, scleral, and punctal.

### Claim 41 (depends on 36)

The method of claim 36 wherein the hydrogel is placed through a 25 gauge or finer needle into the target tissue.

### Claim 42 (depends on 36)

The method of claim 36 wherein the hydrogel is placed in a tissue, in an organ, subcutaneously, or intramuscularly.

### Claim 43

A kit comprising an applicator, a hydrogel precursor, and lipophilic particles that comprise a low water soluble lipophilic compound and a therapeutic agent, wherein the lipophilic particles are solid at 20° C. and have a low water solubility in physiological saline at physiological temperature, with the applicator being adapted to deliver a mixture of the particles and the precursor into an eye.

### Claim 44 (depends on 43)

The kit of claim 43 wherein the particles have a melting point of between about 25° C. and about 60° C.

### Claim 45 (depends on 43)

The kit of claim 43 wherein the therapeutic agent comprises a protein, with the protein having a secondary and/or tertiary structure and being released from the microparticles and the medical material in a conformation that is substantially free of denaturation as measurable by enzyme-linked immunosorbent assay and isoelectric focusing.

### Claim 46 (depends on 43)

The kit of claim 43 wherein the lipophilic particles comprise at least one member chosen from the group consisting of lauric acid, capric acid, methyl stearate, and methyl palmitate.

### Claim 47 (depends on 43)

The kit of claim 43 wherein the low water soluble lipophilic compound has a molecular mass of no more than about 2000 Daltons.

### Claim 48 (depends on 43)

The kit of claim 43 wherein the therapeutic agent comprises a drug with a log P of more than about 2.

### Claim 49 (depends on 43)

The kit of claim 43 wherein the low water soluble lipophilic compound has a log P of at least about 2.
